PURPOSE: The objective of this report is to provide updated guidance in developing an appropriate analytical scope of testing for novel psychoactive substances (NPS) in the United States (and around the world) based on current trends and intelligence. This report is based on information available in Q3 2025 and early Q4 2025 and is subject to change along with the drug market.

**SUMMARY:** The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation of NPS. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. CFSRE's NPS Discovery and the SOFT NPS Committee have established the below recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national and international perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are listed for each NPS. These values are categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class.

BENZODIAZEPINES OPIOIDS		STIMULANTS & HALLUCINOGENS		SYNTHETIC CANNABINOIDS		SEMI-SYNTHETIC CANNABINOIDS		MISCELLANEOUS			
				TIER ONE (S	TRON:	GLY RECOMMEND)					
Bromazolam	1-10	Carfentanil	<]	2/3/4-Methylmethcathinone	>10	5F-MDMB-PINACA (5F-ADB)	<1	THCP	1-10	Medetomidine	1-1
Phenazolam	1-10	Metonitazene	<1	alpha-PiHpP / alpha-PHpP	>10	MDMB-4en-PINACA	<1	Δ <sup>8</sup> -THC	1-10	Xylazine	1-
Desalkylgidazepam <sup>†</sup>	1-10	Protonitazene	<1	N-Isopropyl Butylone	>10	ADB-BINACA (-BUTINACA)	<1	Δ <sup>8</sup> -THC-COOH	1-10	Mitragynine	>
Flubromazepam	1-10	o/m/p-Methylfentanyl	1-10	2F-2oxo-PCE / Fluorexetamine	>10	ADB-4en-PINACA	<1	9(R)-HHC / 9(S)-HHC	1-10	70H-Mitragynine	1-
8-Aminoclonazolam‡	1-10	o/m/p-Fluorofentanyl	1-10	*2/3/4-Chloromethcathinone	>10	MDMB-BINACA (-BUTINACA)	<1	9(R)-HHC-COOH / 9(S)-HHC-COOH	1-10	*Pseudoindoxyl Mitragynine	1-1
				TIER T\	NO (R	RECOMMEND)					
Clonazolam‡	<1	N-Pyrrolidino Protonitazene	<]	*N,N-Dimethylpentylone	>10	*4F-MDMB-BINACA (-BUTINACA)	<1	Δ <sup>10</sup> -THC	1-10	₹4-AcO-DMT	1-
*Ethylbromazolam	1-10	N-Pyrrolidino Isotonitazene	<1	Pentylone	>10	ADB-CHMINACA	<]	Δ <sup>10</sup> -THC-COOH	1-10	Tianeptine	>
Flualprazolam	1-10	<i>N</i> -Pyrrolidino Etonitazene	<1	alpha-PiHP/alpha-PHP	>10	4CN-CUMYL-BINACA (-BUTINACA)	<1	THC-O-Acetate	1-10	Dextro/Levo Methorphan	>
Etizolam†	1-10	N-Pyrrolidino Metonitazene	<1	MDPHP / MDPiHP	>10	5F-MDMB-PICA	<1	HHC-O-Acetate	1-10	Kavain & Kavalactones	>
				TIER T	HREE	(CONSIDER)					
*Ethylflualprazolam	1-10	Spirochlorphine	<]	2C-B	<1	4F-MDMB-BICA	<1	HHCP	1-10	*Etomidate	1-
Desalkylflurazepam <sup>†</sup>	1-10	N-Propionitrile Chlorphine*	<]	N-Cyclohexyl Methylone	>10	MDMB-INACA	<1	CBDP	1-10	Phenibut	>
Pyrazolam	1-10	*5,6-Dichloro Desmethylchlorphine*	<7	Eutylone	>10	ADB-INACA	<1	ННСН	1-10	BTMPS	>
*Flubromazolam	1-10	*N-Pyrrolidino Ethylene Isotonitazene	<]	2F-MBZP / 4F-MBZP	>10	*AMB-CHMINACA	<]	THCM	1-10	TMF-Related Substances <sup>™</sup>	>

\*N-Propionitrile Chlorphine (Cychlorphine) & \*5,6-Dichloro Desmethylchlorphine (SR-17018)



(SOFT) NPS Committee in collaboration with the Center for Forensic Science Research and Education (CFSRE) at U.S. Department of Justice (Award Number 15PNIJ-24-GK-00981-COAP, "Novel Psychoactive Substance Discovery the Fredric Rieders Family Foundation. This report was prepared by Alex Krotulski, Kayla Ellefsen, Donna Papsun, Elisa Shoff, Svante Vikingsson, Michael Truver, Celia Modell, Lana Goodson, Sandrine Mérette, Arny Patton, Helen Chang, Jillian Neifeld, and Barry Logan. The authors would like to acknowledge scientists and staff at our laboratories for their related involvements and contributions.

The recommendations in this report are subject to change with time as new information becomes available. †Toxicologists should consider that NPS may appear due to varying pharmaceutical origins.

These scope recommendations were developed by the Society of Forensic Toxicologists Funding CFSRE's NPS Discovery is funded in-part by the National Institute of Justice, Office of Justice Programs, Education, and Reporting Institute [NPS DiscERn]"). The opinions, findings, conclusions and/or recommendation expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.

> Suggested Citations Krotulski et al. (2025) Recommended Scope for NPS Testing in the United States Q4 2025, Center for Forensic Science Research and Education, United States

PROVIDE FEEDBACK: If you are interested in providing feedback to the SOFT NPS Committee and CFSRE's NPS Discovery program on specific drugs and/or drug classes, the content and formatting of our latest scope recommendations, topics related to NPS and/or NPS testing, or any other items of interest, please email us at npsdiscovery@cfsre.org.

RECOMMENDED NPS METABOLITES: Our recommendations now encompass metabolites of specified NPS to consider in testing scopes, when known or postulated with high certainty based on literature or prior drug similarity. Laboratories should note the following: NPS metabolize to more than one metabolite. Determining the primary metabolite can be difficult and variable based on a variety of factors. NPS metabolites are found at varying abundances in different matrices. This is not intended to be an exhaustive list. Some metabolites listed may be predictive.

RECOMMENDED METABOLITES FOR SPECIFIC NPS										
Bromazolam ► alpha-Hydroxy Bromazolam	Metonitazene ►  N-Desethyl Metonitazene & 5-Aminometonitazene	<i>N,N</i> -Dimethylpentylone ► Pentylone	MDMB-4en-PINACA ►  MDMB-4en-PINACA 3,3-Dimethylbutanoic Acid	Δ³-THC ► Δ³-THC-COOH						
Desalkylgidazepam ► 3-Hydroxy Desalkylgidazepam	Protonitazene ►  N-Desethyl Protonitazene & 5-Aminoprotonitazene	N-Isopropyl Butylone ► N-Desalkyl Butylone	5F-MDMB-PINACA (5F-ADB) ►  5F-MDMB-PINACA 3,3-Dimethylbutanoic Acid	9(R)-HHC / 9(S)-HHC ► 9(R)-HHC-COOH / 9(S)-HHC-COOH						
Flubromazepam ► 3-Hydroxy Flubromazepam	N-Pyrrolidino Protonitazene & N-Pyrrolidino Isotonitazene ► N-Pyrrolidino 4'-OH Nitazene	2F-2-oxo-PCE ► 2F-Deschloronorketamine	ADB-BINACA (-BUTINACA) ►  ADB-BINACA N-Butanoic Acid & MDMB- BINACA 3,3-Dimethylbutanoic Acid	Δ¹º-THC <b>►</b> Δ¹º-THC-COOH						
Phenazolam ► alpha-Hydroxy Phenazolam	N-Desethyl Isotonitazene ►  N,N-Didesethyl Isotonitazene & 5-Amino N-Desethyl Isotonitazene	2/3/4-Methylmethcathinone ► 2/3/4-Methylcathinone	ADB-4en-PINACA ►  MDMB-4en-PINACA 3,3-Dimethylbutanoic Acid	Medetomidine ► 3-Hydroxy Medetomidine						
Flualprazolam ► alpha-Hydroxy Flualprazolam	N-Pyrrolidino Etonitazene ► N-Pyrrolidino 4'-OH Nitazene	2/3/4-Chloromethcathinone ► 2/3/4-Chlorocathinone	MDMB-BINACA (-BUTINACA) ►  MDMB-BINACA 3,3-Dimethylbutanoic Acid	Xylazine ► 3-Hydroxy Xylazine						
Clonazolam ► 8-Aminoclonazolam	N-Desethyl Isotonitazene ►  N,N-Didesethyl Isotonitazene & 5-Amino N-Desethyl Isotonitazene	alpha-PiHP/alpha-PHP ► beta-Hydroxy-alpha-PiHP/ beta-Hydroxy-alpha-PHP	ADB-CHMINACA ► MDMB-CHMINACA 3,3-Dimethylbutanoic Acid	Mitragynine ► 7-Hydroxy Mitragynine & Pseudoindoxyl Mitragynine						
Carfentanil ► Norcarfentanil	o/m/p-Fluorofentanyl ► o/m/p-Fluoronorfentanyl	o/m/p-Methylfentanyl ► o/m/p-Methylnorfentanyl	4CN-CUMYL-BINACA (-BUTINACA) ► 4CN-CUMYL-BINACA N-Butanoic Acid	4-AcO-DMT ► Psilocin						



(SOFT) NPS Committee in collaboration with the Center for Forensic Science Research and Education (CFSRE) at U.S. Department of Justice (Award Number 15PNI)-24-GX-00981-COAP, "Novel Psychoactive Substance Discovery, the Fredric Rieders Family Foundation. This report was prepared by Alex Krotulski, Kayla Ellefsen, Donna Papsun, Elisa Shoff, Svante Vikingsson, Michael Truver, Celia Modell, Lana Goodson, Sandrine Mérette, Amy Patton, Helen Chang, Jillian Neifeld, and Barry Logan. The authors would like to acknowledge scientists and staff at our policies of the U.S. Department of Justice. aboratories for their related involvements and contributions.

The recommendations in this report are subject to change with time as new information becomes vailable. Toxicologists should consider that NPS may appear due to varying pharmaceutical origins.

These scope recommendations were developed by the Society of Forensic Toxicologists Funding CFSRE's NPS Discovery is funded in-part by the National Institute of Justice, Office of Justice Programs, Education, and Reporting Institute [NPS DiscERn]"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or

Suggested Citations Krotulski et al. (2025) Recommended Scope for NPS Testing in the United States Q4 2025, Center for Forensic Science Research and Education, United States